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Abstract
Clear cell renal carcinomas (ccRCCs) can display intratumor heterogeneity (ITH). We applied 
multiregion exome sequencing (M-seq) to resolve the genetic architecture and evolutionary 
histories of ten ccRCCs. Ultra-deep sequencing identified ITH in all cases. We found that 73–75% 
of identified ccRCC driver aberrations were subclonal, confounding estimates of driver mutation 
prevalence. ITH increased with the number of biopsies analyzed, without evidence of saturation in 
most tumors. Chromosome 3p loss and VHL aberrations were the only ubiquitous events. The 
proportion of C>T transitions at CpG sites increased during tumor progression. M-seq permits the 
temporal resolution of ccRCC evolution and refines mutational signatures occurring during tumor 
development.
Solid tumor therapeutic and clinical outcomes can differ substantially between individuals 
with similar clinical and pathological characteristics such as tumor type, grade and stage. 
Despite major efforts to identify prognostic and predictive molecular biomarkers with 
superior precision compared to clinical and pathological predictors, only a small number of 
molecular tests have been introduced into routine oncological practice1. We recently found 
evidence, using M-seq of two ccRCCs, of multiple genetically distinct subclones within 
primary tumors or in primary tumors and their metastases2. Our data further showed that 
both ccRCCs had evolved in a branched rather than linear fashion, similar to the branched 
evolution described in leukemia3, glioblastoma4 and colon5, pancreatic6, ovarian7 and breast 
cancers8.
ITH may lead to an underestimation of the genetic complexity of a tumor when single-
biopsy procedures are used. Furthermore, subclonal driver mutations have been shown to 
contribute to the acquisition of drug resistance9. Thus, branched tumor evolution and the 
spatial separation of subclones might contribute to difficulties in efforts to validate 
oncological biomarkers. The presence of subclonal tumor drivers also has implications for 
drug development strategies; targeting of founder events, located on the trunk of a tumor’s 
phylogenetic tree, may prove more effective than targeting of subclonal driver events10.
To resolve ccRCC subclonal architectures, discriminate early from late driver events and 
decipher mutational spectra that occur during the course of ccRCC evolution, we applied M-
seq to eight sporadic ccRCCs and combined these data with those for two previously 
reported cases2. We find that most driver aberrations are confined to spatially separated 
subclones and that the number of driver aberrations identified in individual ccRCCs 
increases with the number of biopsies sampled. Spatial separation of tumor subclones results 
in underestimation of the prevalence of driver mutations on a per-case basis if only a single 
biopsy is considered. Comparison of the mutation spectra of trunk versus branch mutations 
in phylogenetic trees of tumor subclones indicates that mutational processes change during 
tumor evolution.
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RESULTS
Intratumor heterogeneity and spatial separation of subclones
We collected tissue from multiple tumor regions, representing the spatial extent and 
macroscopic heterogeneity of the primary tumors, from each of ten individuals with stage 
T2 (n = 2), T3 (n = 7) or T4 (n = 1) ccRCC obtained by the London Renal Cancer 
Consortium. All except two of these cases (RMH008 and RK26) presented with metastatic 
disease (Supplementary Table 1). Three cases (RMH004, RMH008 and RK26) were 
untreated. Six cases (EV001–EV003 and EV005–EV007) had received treatment with the 
mTOR inhibitor everolimus for 6 weeks and one case (RMH002) received treatment with 
the anti-angiogenic drug sunitinib for 16 weeks before nephrectomy. As previously 
described, samples from a perinephric metastasis (M1) and from a chest wall metastasis 
(M2a and M2b) were available for EV001, and a biopsy from a metastasis obtained at the 
time of disease progression on everolimus treatment was available for EV002 (M)2. Samples 
from a lymph node metastasis for EV006 (LN1a and LN1b) and a tumor thrombus from the 
renal vein of RMH004 (VT) were also included. All subjects provided written informed 
consent for the presented analyses.
EV001 and EV002 have previously been sequenced2, and whole-exome M-seq was 
performed on tumor and normal DNA samples from the other eight cases with a target depth 
of >70× per sample (Supplementary Table 2). Overall, 679 nonsynonymous nucleotide 
substitutions and insertions and deletions (indels) were detected in at least 1 region and were 
subjected to ultra-deep amplicon sequencing (average depth of >400×) for validation, with 
the exception of 28 mutations for which PCR amplicons could not be generated. We 
successfully validated 92.5% (602/651) of mutations (for mutation details, see 
Supplementary Table 3), and 49 mutations that failed validation were removed from the 
analysis. We identified somatic mutations in the von Hippel–Lindau gene (VHL), which is 
inactivated in up to 90% of ccRCCs11, in all tumors except EV003. Bisulfite treatment 
identified VHL DNA methylation, described previously to result in gene inactivation12, in all 
tumor regions of EV003 (Supplementary Fig. 1).
We determined the regional distribution of nonsynonymous mutations on the basis of data 
from ultra-deep amplicon sequencing. We called a mutation as being present in a tumor 
region if a nucleotide substitution was detected in ≥0.5% of reads or an indel was detected in 
≥1% of reads. We chose these thresholds on the basis of the error rate of the sequencing 
platform13. The regional distribution of 28 mutations for which ultra-deep sequencing data 
were not available was inferred from the exome sequencing data. Exome sequencing of 
EV001 and EV002 has previously been reported2 and was included in this analysis. On 
average, 67% (range of 28–92%) of the nonsynonymous somatic mutations were 
heterogeneous and not detectable across all sampled regions of an individual tumor (Fig. 1). 
The presence of somatic mutational heterogeneity in all (10/10) treatment-naive or 
pretreated cases indicates that ITH, characterized by the spatial separation of subclones, is a 
common feature in stage T2–T4 ccRCCs.
To identify the optimal number of biopsies that can reliably detect the majority of 
nonsynonymous somatic mutations in a tumor, we calculated the number of mutations that 
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would have been detected from each tumor by sampling one to n biopsies (where n was the 
number of biopsies sampled from that tumor), taking into account all permutations of the 
available biopsies (Supplementary Fig. 2). Although mutation detection seemed to plateau 
off with increasing biopsy number in some cases (EV001, EV003 and EV007), a persistent 
increase in the number of detected mutations was apparent with each additional biopsy in 
the other seven cases. Thus, a further increase in the number of sampled tumor regions 
might result in the identification of additional subclones. Therefore, our M-seq approach 
probably still underestimates the number of mutations present in many ccRCCs.
The two tumors with the lowest extent of mutational heterogeneity (EV003 and EV006) had 
been pretreated with everolimus for 6 weeks before nephrectomy. One possible explanation 
for this finding might be the elimination of subclones with high sensitivity to drug. 
However, everolimus is a cytostatic agent14 that is unlikely to lead to substantial depletion 
of cancer cells. In addition, the largest diameters of these tumors only showed minor 
shrinkage over the treatment period (EV003, −1%; EV006, −8%), similar to decreases in 
diameter observed in the more heterogeneous cases with everolimus pretreatment 
(Supplementary Table 4). Thus, everolimus therapy is unlikely to have led to a dramatic 
depletion of subclones and a reduction in heterogeneity specifically in EV003 and EV006. 
No other clinical or pathological characteristic seemed to correlate with mutational ITH, and 
larger series will be required to determine the biological basis for the diversity in ccRCC 
phylogenetic structures.
Identification of intraregional subclones
Variant allele frequencies (VAFs) for aberrations from all eight cases that had been 
validated by ultra-deep sequencing were analyzed to investigate whether multiple subclones 
could be found in individual regions. Mutations at positions with a sequencing depth of less 
than 100× in one or more tumor regions were excluded from the analysis to ensure accurate 
VAFs. Regional VAFs for the remaining 587 mutations (Supplementary Table 5) are shown 
(Fig. 2).
Six of 62 regions showed clear evidence of multiple subclones (EV005 R6, EV007 R3 and 
R9, RMH008 R4 and R6, and RK26 R5). These subclones were identifiable by clusters of 
mutations with consistently low VAFs compared to other mutations in the same region (Fig. 
2) and by the presence of two distinct large peaks in density plots (Supplementary Fig. 3). 
Mutation clusters defining these minority clones were present in a dominant clone in another 
tumor region in all cases. For example, the minority clone detected in EV007 R3 was 
present as a dominant clone in R4 and R9.
Resolving intraregional subclonal structures has implications for phylogenetic analysis. For 
example, 13 of 38 mutations found ubiquitously by M-seq in all regions of EV005 showed 
subclonal VAFs in R6, defining an intraregional minority clone. Hence, although these 13 
mutations were detected in all regions, they were not located on the trunk of the 
phylogenetic tree. Similarly, a mutation in the tumor suppressor gene BAP1 that was 
detected ubiquitously in EV007 appeared to be subclonal in R4 and R9, also indicating that 
it was not a truncal mutation.
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Additional regional mutations demonstrated low VAFs compared to ubiquitous mutations in 
the same tumor region, suggesting the presence of further intraregional subclones, similar to 
previous reports in ccRCC15. However, these subclonal structures could not be further 
resolved because of the limited number of mutations available for analysis from exome 
sequencing data and the lack of integer copy number data, precluding the application of 
more refined methods for the reconstruction of subclonal structures16,17.
ccRCC life histories mapped by phylogenetic analysis
We constructed phylogenetic trees for these tumors by maximum parsimony (Fig. 3). 
Mutations in the polyclonal regions described above were separated into mutations likely to 
be present in the dominant or minority subclones (Supplementary Table 6), and both classes 
of mutations were plotted. Similar to our previous report2 of EV001 and EV002, all tumors 
showed a branched evolutionary pattern, indicating that a linear model inadequately portrays 
ccRCC evolution.
Identification of truncal and branched driver mutations
Next, we mapped driver mutations onto the phylogenetic trees to address whether specific 
driver genes were predominantly altered on trunks or branches. Nonsynonymous mutations 
were classified into three categories: (i) category 1 ‘high confidence driver mutations’ 
(amino acid substitutions identical to those found previously in cancer driver genes or 
disrupting mutations (frameshift, nonsense and splice-site mutations) in tumor suppressor 
genes as defined by large-scale sequencing efforts in ccRCC15,18–21 or by the Catalogue of 
Somatic Mutations in Cancer (COSMIC) Cancer Gene Census22); (ii) category 2 ‘probable 
driver mutations’ (mutations leading to amino acid changes in ccRCC driver or COSMIC 
Cancer Gene Census genes that have not previously been described but affect amino acids 
that have been previously found to be altered based on COSMIC or one up to five amino 
acids away from an amino acid affected by a mutation in a ccRCC driver gene); and (iii) 
category 3 ‘mutations of unknown relevance’ (all other nonsynonymous somatic mutations). 
This approach identified 45 category 1 driver mutations and 4 category 2 driver mutations in 
our 10 cases (Supplementary Table 7). Methylation of the VHL gene in EV003 was also 
classified as a category 1 driver event as it has been described to result in VHL 
inactivation12. Mutated driver genes are highlighted in Figures 1 and 2 and were mapped 
onto the phylogenetic trees (Fig. 3). Most regions harboring PBRM1 or BAP1 mutations 
displayed gene expression profiles concordant with those described for each of these driver 
aberrations23 (Supplementary Fig. 4), and regions harboring a BAP1 or TP53 mutation 
showed a trend toward higher grade (P = 0.056) as described24 (Supplementary Fig. 5), 
suggesting that the identified driver mutations have functional consequences.
VHL-inactivating alterations were present on the trunks of the phylogenetic trees for all ten 
tumors, consistent with the role of inactivation of the VHL tumor suppressor gene as a 
critical founder event in the majority of ccRCCs25. Mutations of the PBRM1 tumor 
suppressor gene, the second most commonly mutated gene in ccRCC19, mapped onto the 
trunks of the phylogenetic trees for three of the six tumors that harbored a PBRM1 mutation. 
Thus, PBRM1 inactivation occurs early in a subgroup of tumors. All other driver mutations 
were located on the branches of the phylogenetic trees. In total, 36 driver mutations (73%) in 
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14 genes were subclonal, and only 13 somatic driver alterations (27%) in 2 genes were 
truncal. Thus, the majority of driver mutations detected in these ccRCCs appear to be 
spatially separated and subclonal. We further examined density plots (Supplementary Fig. 3) 
for 52 tumor regions harboring at least 1 driver mutation to determine whether driver 
mutations showed evidence of intraregional subclonality (Supplementary Note). As 
expected, none of the 48 truncal driver mutations were subclonal. However, although driver 
mutations on branches were heterogeneous in all tumors where they had been detected, only 
16 of 56 (29%) of these driver mutations also appeared subclonal within individual regions, 
and the remaining 40 (71%) appeared clonally dominant in individual regions. These 
findings show that the detection of a clonally dominant driver in one tumor region does not 
predict clonal dominance in the entire tumor.
Parallel evolution of subclones
We previously demonstrated2 parallel evolution involving multiple independent mutations 
converging on the tumor suppressor genes SETD2, KDM5C and PTEN in EV001 and 
EV002. Here we identified parallel evolution in four additional tumors—EV005 harbored 
two distinct and spatially separated activating mutations26 in PIK3CA (encoding 
p.Glu545Lys and p.His1047Arg), EV007 carried two spatially separated mutations in the 
SETD2 histone methyltransferase (encoding p.Tyr545* and p.Thr1652Ile), and RMH008 
harbored three spatially separated mutations in the histone deubiquitinase BAP1 (encoding 
p.Gln277*, p.Asn411fs and p.Pro519fs). RMH004 harbored two distinct mutations in 
PBRM1 (encoding p.Lys1282fs and p.Leu207fs) and one mutation each in ARID1A 
(encoding p.Arg1020Lys) and SMARCA4 (encoding p.Thr910Met), all components of the 
SWI/SNF chromatin-remodeling complex. Parallel evolution events converging on distinct 
genes or on multiple genes encoding subunits of multiprotein complexes indicate that there 
is strong selection for these mutations in these particular tumors.
Identification of heterogeneous copy number driver events
We previously demonstrated ITH of somatic copy number aberrations (SCNAs) by SNP 
array profiling in ccRCC2,27. We now sought to investigate whether predominantly truncal 
(analogous to VHL mutations) or branched (analogous to SETD2 or BAP1 mutations) driver 
copy number events could be identified in SCNA profiles reconstructed from the exome 
sequencing data. We excluded regions with low tumor content, defined by a median VAF 
for truncal mutations of <15% (EV003 R6; EV006 R3 and N1b; EV007 R2, R5 and R7; 
RMH002 R2; RMH008 R1 and R3; and RK26 R6, R7 and R9) and regions showing flat 
SCNA and B-allele frequency profiles, most likely indicating technical failure (EV001 R8; 
EV002 R1 and R7; EV003 R5; EV007 R4; and RMH002 R1), leaving 61 regions for 
analysis. We identified putative driver events by overlapping SCNA profiles with recurrent 
regions of DNA copy number gain or loss, previously defined as likely driver aberrations in 
ccRCC28 (Supplementary Fig. 6). Overall, 75% (57/76) of all driver SCNAs were 
heterogeneous and spatially separated (Fig. 4). Driver SCNA heterogeneity positively 
correlated with nonsynonymous (r = 0.553) and driver (r = 0.684) mutation heterogeneity 
(Supplementary Fig. 7), indicating that mutational and SCNA diversity were not mutually 
exclusive but often occurred together in these ccRCC cases.
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The only driver SCNA found in all regions of all ten tumors was chromosome 3p loss, 
which evolved into copy-neutral loss of heterozygosity (LOH) in some subclones 
(Supplementary Fig. 8), underscoring the importance of this aberration together with VHL 
somatic mutations as founder events in ccRCC tumorigenesis. Losses on chromosomes 4q, 
8p and 14q and gains of chromosome 5q were ubiquitously detected in some tumors but also 
occurred as heterogeneous aberrations in other cases, indicating that they are not obligatory 
truncal events in every tumor in which they occur. We could map 63 of 76 driver SCNAs 
onto the trunk or a single branch of the phylogenetic trees generated from point mutation 
data, indicating that the evolutionary histories identified using mutation and SCNA data 
were highly concordant (Supplementary Fig. 9). The regional distribution of the remaining 
13 driver SCNAs could not be explained by a single event. These aberrations might have 
evolved independently on multiple occasions within individual tumors. Alternatively, 
SCNAs acquired in a single event might have been reversed through subsequent events in 
some subclones, or minor inaccuracies in the phylogenetic trees generated from point 
mutation data might account for these differences. Furthermore, ubiquitous chromosomal 
events might have been acquired early as truncal alterations; however, they could also be the 
consequence of parallel evolution of SCNAs that appeared to be similar but originated 
independently in distinct subclones within individual tumors. This scenario is likely for the 
chromosome 8p loss that was found ubiquitously in EV006 but displayed two different 
SCNA profiles (Supplementary Fig. 6). Exact breakpoint mapping using higher resolution 
techniques would be necessary to determine whether similar SCNA driver events in 
different regions are related and to unequivocally map them onto phylogenetic trees.
Our data suggest that driver mutations and SCNAs can be classified into (i) predominant 
truncal drivers, such as chromosome 3p loss and VHL mutations, which are likely to be 
necessary to initiate tumor growth in the majority of ccRCCs; (ii) facultative truncal drivers, 
such as PBRM1 mutation, which in some cases may be acquired early but which can also 
occur on branches (such events were located on the trunk in up to 60% of ccRCCs; Fig. 5a); 
and (iii) subclonal drivers, representing the largest group in our data, which were always 
located on branches, suggesting that they may be important for adaptation during disease 
progression.
Driver mutation prevalence
Single-biopsy approaches may underestimate the prevalence of driver mutations in 
heterogeneous tumors. To investigate this possibility, we compared the prevalence of driver 
mutations across the 79 sequenced ccRCC samples to the prevalence of driver mutations in 
102 VHL-deficient ccRCCs in stages T2–T4 analyzed by whole-exome sequencing of single 
biopsies by The Cancer Genome Atlas (TCGA)21. The prevalence of driver mutations in 
these 102 cases was strikingly similar to the prevalence we identified on a per-biopsy basis 
across our 79 samples (Table 1), indicating that the mutational diversity in a large cohort is 
similar to that of a small cohort of cases analyzed through multiple biopsies for each tumor.
However, when we determined the prevalence of driver mutations per case rather than per 
biopsy, the prevalence for most driver genes was higher than that based on individual 
samples sequenced by us or TCGA (Table 1). Most strikingly, TP53 mutations, which were 
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only found in 6% of individual biopsies, were detected in 40% of cases when all tumor 
regions were considered for each. Similarly, mutations in the phosphoinositide 3-kinase 
(PI3K)-mTOR pathway were detected in 28% of individual biopsies; however, 60% of cases 
in our study harbored at least one mutation in this pathway. These data suggest that single-
biopsy approaches underestimate the prevalence of driver mutations in individuals with 
ccRCC.
Mutation spectra of truncal and branch mutations
Somatic cells acquire mutations over the lifetime of an individual. Assuming that most 
truncal mutations occurred before transformation, phylogenetic trees allow us to explore 
whether the mutational spectrum changes as a result of transformation and to gain insights 
into the underlying mutation and DNA repair mechanisms29. The proportion of C>T 
transitions at CpG sites increased significantly in branches (q = 0.007; Fig. 5b). This 
increase was observed in eight of the ten cases (Fig. 5c). The proportion of C>T transitions 
increased in all XpCpG contexts, where X represents any nucleotide (Supplementary Fig. 
10). We also observed a significant decrease in the proportion of A>G transitions (q = 
0.007) among the branch mutations in each case analyzed. This finding indicates that 
specific mutational processes foster the generation of genetic diversity in ccRCC cells.
DISCUSSION
We have identified ITH of somatic mutations and SCNAs in all 10 ccRCCs analyzed by M-
seq and demonstrated that 73–75% (36/49 driver mutations and 57/76 driver SCNAs) of 
genetic driver events were subclonal. ITH increased with the number of biopsies analyzed 
without evidence of saturation in seven of the ten tumors, suggesting that our M-seq 
approach still underestimates ITH. Inactivation of the VHL tumor suppressor gene through 
mutation or DNA methylation and LOH at chromosome 3p were truncal events in all cases. 
This is consistent with the role of these alterations as founding events in most ccRCCs. 
Within the boundaries of current knowledge of ccRCC biology, these two drivers may be 
sufficient to initiate tumor proliferation in cases that did not display any additional truncal 
driver aberrations. We observed truncal PBRM1 mutations and ubiquitous SCNAs on 
chromosomes 4q, 5q, 8p and 14q in up to 60% of affected tumors, demonstrating that these 
alterations can be acquired early, potentially together with VHL and 3p loss, in the founding 
cell of the tumor. We only analyzed ten tumors, and larger series will be necessary to 
determine whether mutations in other driver genes such as TCEB1, which occur recurrently 
in ccRCCs with wild-type VHL15, are also predominantly localized on the trunk.
All other ccRCC driver gene mutations and driver SCNAs were restricted to tumor 
subclones. These alterations were acquired during tumor progression and are likely drivers 
of the expansion of tumor clades, comprising all subclones emerging distally on the 
branches. Regional separation of subclones was the predominant pattern of ITH in all cases. 
This separation may result from spatial barriers limiting subclonal intermixing in solid 
tumors. The parallels with allopatric speciation, resulting from geographic separation 
fostering the evolution of new species, are striking. Driver mutations with relatively small 
selective advantage may also render selective sweeps unlikely, fostering the evolution of 
Gerlinger et al. Page 8
Nat Genet. Author manuscript; available in PMC 2015 November 06.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
spatially separated subclones. The coexistence of subclones with mutations in different 
driver genes in non-overlapping pathways within some tumors (for example, BAP1, PBRM1 
and TP53 mutations in distinct subclones in RK26) suggests that these mutations do not 
define intrinsic molecular subgroups but that individual ccRCCs can traverse different 
evolutionary routes simultaneously.
We previously demonstrated parallel evolution in individual tumors through the 
identification of distinct inactivating mutations in the tumor suppressor genes SETD2 and 
KDM5C or PTEN2. Here we identified four further tumors harboring multiple driver 
mutations converging on PIK3CA, BAP1, SETD2 or PBRM1. Mutational convergence 
affecting different SWI/SNF complex members was seen in one case. Parallel evolution of 
SETD2 mutations occurred in three of the ten tumors, and no SETD2 mutations were 
identified in the remaining seven tumors, suggesting that different tumors may follow 
distinct evolutionary trajectories. It will be important to investigate whether these 
trajectories are determined by selection under specific microenvironmental conditions or 
through epistatic interactions and whether they are predictable and targetable in advance of 
their occurrence.
According to our small data set, truncal driver events are similar across different ccRCCs; 
however, clinical outcomes can differ substantially for individuals with ccRCC. Thus, it is 
likely that the set of subclonal drivers that is acquired by individual tumors during 
progression and that shows high variability between different cases influences clinical 
outcome. The relevance of subclonal drivers for outcome prediction is further illustrated by 
chromosome 9p losses and BAP1 mutations, both markers of poor prognosis in ccRCC24,30, 
which were heterogeneous in all cases where they were identified. The reliable detection of 
such prognostically relevant subclonal drivers is likely to be of paramount importance in 
improving the accuracy of prognostic and predictive biomarkers31.
We found that 71% of driver mutations that were heterogeneous between tumor regions 
appeared clonally dominant within individual regions. This illusion of clonal dominance 
calls into question the ability of single biopsy–based VAF analysis to accurately measure 
heterogeneity and to identify driver alterations that are clonally dominant across an entire 
ccRCC tumor. This finding suggests a need for caution when attempting to define clonally 
dominant driver events from single biopsies for treatment stratification with targeted 
therapeutics.
As the majority of ccRCC driver mutations are heterogeneous, therapeutic targeting of 
truncal drivers such as VHL inactivation or chromosome 3p loss might be an effective 
strategy to improve clinical outcomes10, assuming that tumors remain dependent on these 
drivers throughout their life histories. Both truncal driver events inactivate tumor suppressor 
genes that are not directly targetable. However, these alterations may be exploitable through 
synthetic lethal approaches, as demonstrated for VHL32–34. New treatment personalization 
strategies may also be necessary to improve outcomes in ccRCC. For example, we 
previously suggested that systemic therapy for cancer be readjusted after a partial response 
has been achieved through performing new biopsies of residual tumor masses and specific 
targeting of the molecular drivers of surviving clones9.
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The relative increase in the proportion of C>T transitions in a CpG context and the decrease 
in the proportion of A>G transitions in the mutation spectrum of branch versus truncal 
mutations indicate that specific processes may foster the generation of genetic diversity in 
ccRCC. C>T transitions at CpG sites have been proposed to occur through spontaneous 
deamination of methylated cytosines35, in the same process that dominates the background 
mutation rate in mammalian genomes36. It will be important to investigate whether VHL or 
chromosome 3p alterations contribute to these processes and whether such interactions can 
be exploited for therapeutic purposes. The proportion of C>T transitions at CpG sites 
decreases during breast cancer progression16, highlighting the fact that dynamics of 
mutational processes can vary between different cancer types.
Metastatic tissues were only available for three cases, which is a clear limitation of our 
study. Larger numbers of metastatic sites per case will need to be analyzed to determine 
whether heterogeneity between metastases mirrors the heterogeneity seen within primary 
tumors or whether metastases are relatively homogenous, which might foster the 
development of biomarkers and therapeutics for metastatic ccRCCs.
In conclusion, M-seq identified heterogeneous genomic landscapes and branched evolution 
for each of ten sporadic VHL-deficient ccRCCs with spatially separated subclones, creating 
an illusion of clonal dominance when assessed by single biopsies. The presence of subclonal 
driver events in solid tumors may provide an explanation for the inevitable acquisition of 
resistance to targeted therapeutics in advanced disease. The regional isolation of tumor 
clades in ccRCC, together with extensive evidence of parallel evolution of tumor subclones, 
raises important questions regarding how tumors can be optimally sampled and whether 
future evolutionary tumor branches might be predictable and ultimately targetable.
ONLINE METHODS
Subjects samples and consent
Samples were collected from individuals enrolled in the “Response and Resistance to 
Targeted Therapy in Renal Cell Carcinoma” tissue collection protocol of the London Renal 
Cancer Consortium (ethics approval reference 11/LO/1996) or into the E-PREDICT 
translational clinical trial (EUDRACT number 2009-013381-54; principal investigator J.L.). 
Tissue collection and trial protocols had been approved by an ethics committee, and all 
individuals included in this study had provided written informed consent for the analysis 
presented. EV001–EV007 were consecutively enrolled into the E-PREDICT trial and 
received 6 weeks of preoperative first-line treatment with the mTOR inhibitor everolimus 
before nephrectomy. Samples from EV004 were included in an ongoing study using whole-
genome sequencing in ccRCC and will be published separately. The other four cases were 
enrolled in the renal cell carcinoma tissue collection protocol, and their tumors were chosen 
for M-seq analysis on the basis of ccRCC histology and primary tumor stage of T2–T4. 
Samples were sequenced consecutively. RMH004, RMH008 and RK26 were treatment-
naive cases with a new diagnosis of ccRCC, whereas RMH002 had been treated with the 
anti-angiogenic drug sunitinib for 14 weeks before nephrectomy. Pathological analysis 
confirmed renal cell carcinoma of the clear cell type in all cases (see Supplementary Table 1 
for clinical and pathological characteristics).
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Tumor specimen processing
We isolated between 8 and 20 samples of 10 × 5 × 5 mm, representing the spatial extent and 
macroscopic heterogeneity of the primary tumor, from each nephrectomy specimen. 
Samples were macrodissected to minimize stromal contamination, and half of each sample 
was snap frozen in liquid nitrogen within 1 h of clamping of the renal artery. Sample 
collection was performed according to strict standard operating procedures in all cases and 
was documented by photography. DNA and RNA were extracted using the Qiagen AllPrep 
kit following the manufacturer’s instructions. Nucleic acid yields were determined by Qubit 
(Invitrogen), and quality and integrity of DNA was examined by agarose gel electrophoresis. 
We excluded regions that did not contain tumor cells on histopathological examination, and 
we selected up to 12 regions per tumor from which sufficient high-quality DNA was 
available for exome-capture library preparation for exome sequencing.
M-seq multiregion exome sequencing
Exome capture was performed on 3–6 μg of genomic DNA per sample with the Agilent 
SureSelect Human All Exon V4 kit according to the manufacturer’s instructions, and paired-
end multiplex sequencing of samples on the Illumina HiSeq platform was performed at the 
Beijing Genome Institute (BGI) (EV003, EV005, EV006 and EV007) or on the Illumina 
Genome Analyzer II and HiSeq platforms at the Cancer Research UK London Research 
Institute (LRI) (RMH002, RMH004, RMH008 and RK26). In brief, genomic DNA 
sequenced at LRI was randomly fragmented by Covaris to obtain fragments mainly 
distributed between 250 and 300 bp in length. Adaptors were ligated to both ends of the 
fragments, adaptor-ligated templates were purified using Agencourt AMPure SPRI beads, 
and fragments with an insert size of about 250 bp were excised. Extracted DNA was 
amplified by ligation-mediated PCR (LM-PCR), purified and hybridized to the SureSelect 
Biotinylated RNA Library (BAITS) for enrichment. Hybridized fragments were bound to 
streptavidin beads, whereas non-hybridized fragments were washed out after 24 h. Each 
captured library was loaded on the Illumina platform, and paired-end sequencing was 
performed to the desired median sequencing depth (>70×). Raw image files were processed 
using HCS1.4.8 for base calling with default parameters.
M-seq bioinformatics analyses
Paired-end reads in FastQ format generated by the Illumina pipeline were aligned to the 
“full” build of hg19 (including unknown contigs), using the Burrows-Wheeler Aligner 
(BWA) 0–5.9 with a seed length of 90 bp for data sequenced at BGI and 100 bp for data 
from LRI. All other settings were left as default (in particular, up to 3 or 4 mismatches were 
allowed per read for data from BGI or LRI, respectively). Variant calling was performed 
using CAVEMAN as described19. The following filtering criteria were applied to the called 
variants: (i) only nucleotides with Phred quality of 20 or greater were considered; (ii) only 
reads mapping uniquely to the genome were considered; (iii) a minimum of 10× coverage in 
both germline and tumor samples was required; (iv) a minimum of two instances of the 
variant in the tumor region were required; and (v) variants in positions listed in dbSNP132 
were removed. Somatic mutations present in at least 5% of the reads on the basis of exome 
sequencing in at least one tumor region were further analyzed. Filtering was performed 
Gerlinger et al. Page 11
Nat Genet. Author manuscript; available in PMC 2015 November 06.
 E
urope PM
C
 Funders A
uthor M
anuscripts
 E
urope PM
C
 Funders A
uthor M
anuscripts
using R 2.15.0, the Bioconductor packages ShortRead and deepSNV, and in-house parsers 
written in C. Variants were annotated as synonymous or nonsynonymous using both 
dbNSFP and Annovar. Small indels were identified using Pindel37 version 0.2.437 in paired 
tumor-normal mode. In-house filter software was used to extract high-quality indels: 
considering the high sequence coverage obtained in these samples, only indels with 
minimum coverage by 20 reads in both tumor and normal samples, a minimum frequency of 
10% of the reads, a minimum of 5 independent reads supporting the event in the tumor 
sample and no evidence of the event in the normal sample were considered. All 
nonsynonymous candidate mutations were reviewed on the Integrated Genomics Viewer38 
(IGV), and variants only present in poorly aligned reads and those showing an Illumina-
specific error profile39 were removed. The known ccRCC driver genes VHL, PBRM1, 
SETD2, BAP1, KDM5C, MTOR, TP53, PIK3CA and PTEN were also reviewed manually on 
IGV to reduce the false negative rate.
Bisulfite sequencing of the VHL gene
Identification of methylation of the VHL gene of EV003 was carried out after bisulfite 
treatment of 500 ng of DNA from each tumor region and normal kidney sample using the 
EZ DNA Methylation kit (Zymo Research). Oligonucleotides were designed using 
MethPrimer to amplify a 321-bp PCR fragment spanning exon 1 and continuing into intron 
1 of VHL from nucleotide positions chr. 3: 10,183,739–10,184,059. PCR products were 
sequenced using BigDye Terminator technology on an ABI 3730, and the presence or 
absence of guanine conversion to uracil at CpG sites in the sequence was used to determine 
methylation.
Mutation validation and variant frequency analysis
For all tumors except EV001 and EV002, an AmpliSeq (Lifetech) validation panel was 
designed by entering the genomic positions of all nonsynonymous somatic mutations called 
in at least one region into the Ion AmpliSeq Designer (150-bp amplicon size option 
selected). Multiplex PCR was performed according to the manufacturer’s instructions with 
the tumor-specific primer pool on DNA from each region of the relevant tumor. Amplicon 
pools were used for the construction of barcoded sequencing libraries, and these were 
multiplex sequenced with 200-bp read length on the Ion Torrent PGM sequencer (Lifetech). 
Validation data were reviewed on IGV, and VAF (total reads at the position carrying the 
variant/read depth at the position) values were extracted. Twenty-eight nonsynonymous 
mutations failed amplification, either because the AmpliSeq Designer could not generate 
suitable primers or because primer pairs failed in PCR. Four driver gene mutations were 
affected by this (EV005, VHL; EV006, VHL; RMH002, VHL; and RK26, BAP1), but all of 
these were successfully validated by conventional capillary sequencing. The remaining 24 
mutations were included in the analysis, as the high validation rate of >90% indicated that 
the majority of these were likely to be correct calls. A tumor region was called positive for a 
specific nucleotide substitution if the mutation was present in 0.5% or more of the reads 
covering the position in this region or if an indel was present in at least 1% of reads in the 
Ion Torrent sequencing data. Regional mutation heat maps were constructed on the basis of 
these regional presence/absence calls.
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Variant frequencies extracted from the AmpliSeq validation data were plotted as bar charts 
for all mutations with a minimum coverage of 100× across all sequenced regions of a tumor 
using the R software package. These charts were converted into three-dimensional bar charts 
using Adobe Illustrator. Three-dimensional charts were examined for evidence of 
intraregional subclones. A mutation that displayed low VAF compared to the majority of 
ubiquitous mutations in the same region could indicate the presence of an intraregional 
subclone. However, low VAFs could also be caused by an SCNA at the position of a 
somatic mutation. Thus, intraregional subclones were only defined if a group of three or 
more mutations could be identified in which mutations all had similar VAFs that were 
clearly below the VAFs of the majority of ubiquitous mutations in the same region and if 
these mutations were spread across different chromosomes, reducing the probability that the 
low VAFs were merely a result of SCNAs. The minority and dominant clones that were 
defined through this process were separated in the binary heat maps demonstrating the 
regional distribution of mutations before phylogenetic tree reconstruction (Supplementary 
Table 6). Private mutations that were present in a region with a dominant and a minority 
clone were assigned to the subclone to which the VAFs of the private mutations were most 
similar. For those regions where the median VAFs of two intraregional subclones were 
similar and private mutations could not be assigned to one or the other, private mutations 
were equally distributed between the two subclones. The intraregional subclones in EV001 
R4 have previously been described2 and were included in Supplementary Table 6.
Individual mutations displaying low VAFs were generally not used to define intraregional 
subclones, as we were not able to reconstruct copy number profiles for all sequenced regions 
and could therefore not discriminate whether such single outliers were the result of 
subclonal structures or copy number changes. The single exception was the category 1 
driver mutation detected in the BAP1 tumor suppressor gene in EV007, which we identified 
as a subclonal mutation in R4 and R9. A SCNA event as the underlying reason for the low 
VAFs of this mutation in R4 and R9 appeared unlikely, as the mutation was located within 
the ubiquitous chromosome 3p LOH region in this tumor. Thus, if this mutation had been 
acquired on the trunk of the phylogenetic tree and was followed by a ubiquitous 
chromosome 3p LOH event that eliminated the wild-type allele, then a reduction in VAF 
could only be explained by a further loss affecting the chromosome 3p allele that harbors the 
BAP1 mutation. In this case, no significant allelic imbalance should be detectable in EV007 
R9. As allelic imbalance was clearly present in R9 (Supplementary Fig. 9), the most 
parsimonious explanation was that the BAP1 mutation was acquired after LOH at 
chromosome 3p and defined a subclone that was present at very low frequency in R4 and 
R9.
Clonality analysis via kernel density plots
Observed variant frequencies were transformed by dividing all frequencies within a region 
by the median frequency within that region of the ubiquitous variants for that case. For these 
transformed frequencies, a density plot was constructed using the R function density(), with 
a “cosine” kernel (strictly speaking, (1 + cos (πx))/2 for x in [−1,1]) and 128 interpolation 
points.
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Mutation numbers detected by a fixed number of biopsies
For each tumor, we calculated the total number of mutations detected in each possible subset 
of regions of size 1, 2, …, n, where n was the total number of biopsies taken from that 
tumor. For example, in a tumor for which three regions were available, we examined the 
following subgroups: R1, R2, R3, R1 + R2, R1 + R3, R2 + R3, and R1 + R2 + R3. Then, for 
each fixed subset size, we calculated the mean number of mutations detected.
Phylogenetic analysis
The heat maps in Supplementary Table 6 showing binary distribution of mutations were 
used for phylogenetic tree reconstruction. Maximum-parsimony trees were inferred using 
the max-mini branch- and-bound algorithm40, calculating branch lengths with the average 
pathway method, as implemented in the MEGA5 package41. The germline sample was 
designated as the outgroup, and, in the event of multiple optimal topologies, a consensus tree 
was constructed by collapsing branches reproduced in less than 50% of the trees. 
Phylogenetic trees were constructed with these algorithms and were redrawn in Adobe 
Illustrator with trunk and branch lengths proportional to the average number of 
nonsynonymous mutations that were acquired on these branches on the consensus tree. 
Angles between branches were chosen only for convenience of display.
Identification of driver mutations
Mutations that failed validation were removed, and all remaining genes carrying 
nonsynonymous somatic mutations were compared with lists of potential driver genes in 
ccRCC. These included the genes found to be recurrently mutated in ccRCC in previous 
studies15,18–21. Genes mutated in our ten cases were also compared to the COSMIC Cancer 
Gene Census (downloaded 7 August 2013), a list of genes assumed to acquire driver 
function though genetic alterations in a variety of human cancers. Genes that were mutated 
in the ccRCCs analyzed by M-seq and were also found in one of these databases were 
analyzed in detail. A list of all identified category 1 and category 2 driver mutations can be 
found in Supplementary Table 7. Two mutations in KDM5C identified in EV001 R1, R2, 
R3, R5, R8 and R9 were always detected together in close proximity on the same allele and 
were counted as a single driver event.
Analysis of driver mutation prevalence
We downloaded the supplementary tables containing somatic mutation and clinical data for 
the ccRCC cases analyzed by TCGA21. We identified 102 VHL-mutant cases with a primary 
tumor stage of T2–T4, similar to our 10 cases, and determined the prevalence of 
nonsynonymous somatic mutations in PBRM1, SETD2, BAP1, KDM5C, TP53, ATM, 
ARID1A, PTEN, MTOR, PIK3CA and TSC2 in this cohort.
mRNA gene expression profiling
Samples from EV001 have previously been analyzed (GSE31610 archive in the GEO 
repository)2. RNA was extracted from all other tumor specimens and from normal kidney 
specimens obtained from the same individuals and quantified on an Agilent Bioanalyzer. 
mRNA expression profiling was performed on the Affymetrix HuGene-1_0-st-v1 platform 
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by an external service provider for 56 tumor regions and for 6 specimens from normal 
kidney from which sufficient high-quality RNA was available, and data were deposited in 
the GSE53000 archive in the GEO repository. Samples were normalized using the oligo R 
package and the RMA algorithm. A list of the genes differentially expressed in tumor 
samples with BAP1 and PBRM1 mutations was obtained from ref. 23. The expression of 
these genes was assessed for all regions that harbored BAP1 or PBRM1 mutations.
Identification of driver SCNAs
To generate raw copy number estimates, the VarScan2 (v2.2.11) algorithm was employed 
using default parameters except for the data-ratio parameter, which was calculated as 
described42. We excluded regions with low mappability (segmental duplications and 
Encyclopedia of DNA Elements (ENCODE) “DAC blacklisted” regions, as annotated by the 
UCSC Genome Browser). Raw log2-ratio (logR) calls were adjusted for GC content and 
recentered to 0 using the modal logR value determined using kernel density estimates. 
Outliers were detected and modified using Median Absolute Deviation Winsorization before 
case-specific joint segmentation (γ = 300)43, to identify genomic segments of constant logR. 
Adjacent segments of similar logR were merged by an internally developed R script. The 
peak locations of 14 recurrent copy number changes that are likely to be driver copy number 
events in ccRCC were retrieved from Beroukhim et al.28, and these regions were highlighted 
in the logR plots by vertical bars. Blue bars denote recurrently lost peaks (1p36.11, 3p25.3, 
4q34.3, 6q22.33, 8p23.2, 9q21.3 and 14q31.1), and red bars denote recurrently gained peaks 
(1q25.1, 2q14.3, 5q35.3, 7q22.3, 8q24.21, 12p11.21 and 20p13.33). LogR plots were 
reviewed independently by two researchers to determine regional copy number gains and 
losses. Consensus was obtained for diverging results by reviewing LogR plots and B-allele 
frequency plots. Some but not all tumor regions in EV007, RMH002 and RMH004 showed 
copy number losses of chromosome 3p, and all other tumors showed ubiquitous 
chromosome 3p losses. Inspection of the B-allele plots for EV007, RMH002 and RMH004 
showed abnormal B-allele frequencies of chromosome 3p in all regions, suggesting that 
initial LOH at 3p had evolved into copy-neutral LOH by duplication of the remaining allele 
in some regions.
Mutation spectrum analysis
All single nonsynonymous point mutations from all samples were combined in a table and 
defined as occurring on the trunks or branches of phylogenetic trees. A χ2 test was used to 
examine the overall difference in the distribution of trunk and branch mutations, using the 
mutation types listed. Fisher’s exact tests were implemented to assess the difference between 
specific mutation types. For each mutation type, the complementary mutation was also 
assessed; for example, XpCpG to XpTpG and the complementary CpGpX to CpApX. Each 
mutation type was also classified on the basis of its trinucleotide context. P values calculated 
for each of the seven mutation types were corrected for multiple testing using the 
Benjamini-Hochberg method.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Regional distribution of nonsynonymous mutations in ten ccRCC tumors. Mutations that 
failed validation were not included. Heat maps indicate the presence of a mutation (yellow) 
or its absence (blue) in each region. Category 1 high-confidence driver mutations and 
category 2 probable driver mutations are highlighted in magenta. The table shows the 
number of nonsynonymous mutations and the ratio of heterogeneous mutations per tumor. 
An asterisk indicates where VHL methylation was included in the analysis.
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Figure 2. 
Variant frequencies for the nonsynonymous somatic mutations in eight ccRCC tumors based 
on ultra-deep amplicon sequencing. Individual mutations are shown on the x axis, and 
variant frequencies are plotted on the y axis. Category 1 high-confidence driver mutations 
and category 2 probable driver mutations are labeled on the x axis and are highlighted by 
dashed boxes. Amplicon generation for deep sequencing failed for VHL mutations in 
EV005, EV006 and RMH002 and for a BAP1 mutation in RK26, and thus these could not be 
included. Mutations that define dominant (dom) and minority (min) clones in cases EV005, 
EV007, RMH008 and RK26 are indicated.
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Figure 3. 
Phylogenetic trees generated by maximum parsimony from M-seq data for ten ccRCC 
tumors. Trees for EV001 and EV002 are adapted from Gerlinger et al.2. Branch and trunk 
lengths are proportional to the number of nonsynonymous mutations acquired on the 
corresponding branch or trunk. Driver mutations were acquired by the indicated genes in the 
branches the arrows indicate. Driver mutations defining parallel evolution events are 
highlighted by color. Trees are rooted at the germline (GL) DNA sequence, determined by 
exome sequencing of DNA from peripheral blood.
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Figure 4. 
Regional distribution of somatic driver copy number aberrations in ten ccRCC tumors. The 
heat map indicates copy number gains (yellow) or losses (blue) for all tumor regions for 
which copy number profiles could be reconstructed from exome sequencing data. CN, 
regions displaying copy-neutral LOH of chromosome 3p25.3.
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Figure 5. 
Truncal location of driver aberrations and mutation spectrum in ten ccRCC tumors. (a) 
Percentage of cases in which a specific driver aberration was located on the trunk of the 
phylogenetic tree. n indicates the number of cases in which each event was found. Mut, 
mutation; methyl, methylation. (b,c) Mutation spectrum of nonsynonymous trunk versus 
branch mutations combined across all cases (b) and per case (c). The number of mutations 
analyzed is displayed on top of each bar. The difference between the spectra for trunk and 
branch mutations across all cases was assessed using a χ2 test. For specific mutation types, a 
Fisher’s exact test was used, and significant P values, corrected for multiple testing using 
the Benjamini-Hochberg method where appropriate (q values), are shown.
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Table 1
Comparison of driver mutation prevalence in ccRCC samples
Prevalence in TCGA 
samples (n = 102 
samples)
Prevalence in all M-seq 
samples (n = 79 samples)
Prevalence in cases based 
on M-seq (n = 10 cases)
Prevalence cases/
prevalence M-seq 
samples
PBRMl 42% 39% 60% 1.5
SETD2 18% 27% 30% 1.1
BAPl 21% 23% 40% 1.7
KDM5C 7% 11% 10% 0.9
TP53 5% 6% 40% 6.7
ATM 3% 4% 10% 2.5
ARIDlA 6% 1% 10% 10.0
PTEN 5% 10% 20% 2.0
MTOR 9% 8% 10% 1.3
PIK3CA 3% 4% 20% 5.0
TSC2 2% 6% 10% 1.7
PI3K-mTOR pathway 18% 28% 60% 2.1
Comparison of the prevalence of driver mutations in a cohort of 102 VHL-mutant ccRCC samples with stages T2–T4 from TCGA21 and across all 
79 individual samples for the 10 cases sequenced by M-seq in this study. The last column displays the fold increase if prevalence is analyzed on the 
basis of individual cases instead of individual samples. The combined prevalence of the indicated PI3K-mTOR pathway genes (PTEN, PIK3CA, 
TSC2 and MTOR) is shown in the last row.
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